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Summary c-erbB-2 gene amplification and protein over-expression were investigated in 89 primary tumours
and 24 metastases from Norwegian breast cancer patients. Amplification occurred in 22.5% of the primary
tumours and 50% of the metastases. The amplification was negatively correlated to the oestrogen receptor
(ER) content in both the primary tumours and the metastases. No significant differences between amplified
and non-amplified tumours were observed with regard to node status, clinical stage, tumour size or meno-
pausal status, although correlations of borderline significance were found between node status, clinical stage
and high degree of gene amplification. All the amplified tumours were of the invasive ductal type. Follow-up
data of patients observed for more than 1 year showed a significantly higher recurrence rate in the c-erbB-2
amplified group. Allele loss of chromosome 17p and of 17q was seen in 55% and 48% of the tumours
respectively. No significant correlation was found between these losses and clinico-histological parameters.
More than 50% of the tumours with a loss of 17q sequences had an amplification ofc-erbB-2 which is located
on 17ql2-21, indicating that only one of the chromosomes may be involved in the amplification of the
c-erbB-2. A trend towards a correlation between loss of 17q and high degree of amplification were found. No
correlation was found between positive family history of breast cancer and c-erbB-2 gene amplification, nor
loss of 17p or 17q sequences. Our data support the hypothesis that amplification correlates with aggressive
tumour behaviour, and thus may be used as a prognostic factor in breast carcinomas. The allele losses on 17p
and 17q points to tumour suppressor gene or genes on this chromosome, although not as predisposing genes
in families.
The neu oncogene was first identified as a transforming gene
in ethylnitrosurea (ENU) induced rat neuroblastomas (Shih
et al., 1981). The human homologue was cloned by two
independent groups and found to encode a product immuno-
logically related to the epidermal growth factor receptor
(EGFR) and named HER-2 (Coussens et al., 1985) or c-
erbB-2 (Semba et al., 1985). The gene encodes a protein
similar in structure to the EGFR with an external cellular
transmembrane domain and an intracellular domain with
tyrosine kinase activity. The extracellular ligand binding area
is much smaller in c-erbB-2 than in EGFR, and the factor
binding to this putative growth factor receptor is unknown.
A candidate ligand for the c-erbB-2 receptor has recently
been described in conditioned medium from rat cells trans-
formed with the c-Ha-ras oncogene (Yarden & Weinberg,
1989). However, this possible ligand has not yet been puri-
fied, nor has its gene been molecularly cloned, and therefore
formally it is not known whether neu is indeed a growth
factor receptor. In fact this has delayed the progress
in understanding the biology of the frequent amplification
of the c-erbB-2/neu gene in human breast carcinomas,
some ovarian carcinomas and some other adenocarcinomas
(Yokota et al., 1986, 1988; Slamon et al., 1987, 1989; Venter
et al., 1987; Van de Vijver et al., 1988a; Tavassoli et al.,
1989; Wright et al., 1989). Although Slamon et al. (1987) in
an early report showed that the amplification was strongly
correlated to early relapse and death from the disease, the
subject is still a matter of controversies as other groups
measuring gene amplification or protein over-expression
found no correlation to poor prognosis (Ali et al., 1988; van
de Vijver et al., 1988b). The reason for these still contra-
dictory findings could reflect various groups of patients with
different genetic background, geographical location and
nutritional or environmental factors.
The c-erbB-2 gene is located on chromosome 17q12-21.32
(Popescu et al., 1989). Recently there has been a growing
interest in the search for suppressor genes in breast cancers.
Allele loss of chromosome 17 has been observed in a very
high percentage of breast tumours (MacKay et al., 1988;
Devilee et al., 1989). The putative breast tumour suppressor
gene on 17p may be the same as that already noted for colon
and lung cancers, the p53 oncogene/antioncogene, and it has
been suggested that deletion of this gene is one in a cumu-
lative series of lesions involving genetic changes in the evolu-
tion of breast cancer.
The aim of this study has been to investigate the clinical
and biological importance ofc-erbB-2 oncogene amplification
and loss of gene sequences on chromosome 17 in Norwegian
breast cancer patients. Correlation between loss of hetero-
zygosity, gene amplification, positive family history of cancer,




Fresh tumour tissue was obtained from 113 breast cancer
patients admitted to the Norwegian Radium Hospital.
Eighty-nine primary tumours and 24 metastases from differ-
ent individuals were examined. Twenty-two of the metastases
were loco-regional recurrencies and two were distant meta-
stases. One part of the tumour tissue was immediately frozen
and stored in liquid nitrogen for gene amplification studies
and immunohistochemistry. Formalin fixed material from
each case was processed for light microscopy. Survival data
were available in 51 patients observed for more than 1 year.
Mean observation time for these patients were 21.5 months
with a range of 12-50 months. No adjuvant treatment was
given to node negative patients. Adjuvant tamoxifen was
given to pre and post-menopausal node positive patients.
Premenopausal node positive patients were treated with
adjuvant CMF for 6 months.
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EDTA blood (10-20 ml) was drawn from each patient and
stored at -40°C before DNA analysis. Seventy-four of the
patients were interviewed with respect to family history of
any cancers. If the index patient was dead, the family history
of any cancers was traced through relatives. All cancer diag-
noses reported were confirmed by the National Cancer Regis-
try. Family history of breast cancer was considered positive if
one or more first degree relatives have had breast cancer.
Family history was considered negative if the patients had at
least one first degree female relative aged 40 or more without
breast cancer. The histopathological sections from primary
tumours were reexamined by the pathologist and classified
according to WHO recommendations.
DNA analysis
DNA was extracted from tissues using standard procedures
(phenol/chloroform and EtOH precipitation) after mincing
the tissue by a scalpel followed by digestion with proteinase
K in 2% sarcosyl overnight at 4°C. Leucocyte DNA was
isolated by the same method after lysis of the cells in 1%
Triton X-100 followed by digestion with proteinase K in
0.5% SDS at 37°C overnight. Gene amplification of the
DNA was analysed by Southern analysis after digestion with
EcoRI. Hybridisation was performed using a 32P-labelled
c-erbB-2 cDNA probe (Yamamoto et al., 1986). Autoradio-
grams were developed at - 70°C after 1-5 days. The degree
of amplification in individual cases was determined by rehy-
bridising the blots with a 32P-labelled CoOLA2 (Collagen I
proa-2 chain) probe which is located on chromosome 7
(Myers et al., 1983). All the autoradiograms were scanned
using a Kontron IPS Densitometric Scanner, and the degree
of amplification, adjusted for amount of DNA, was deter-
mined.
All the probes were radioactively labelled according to the
random oligolabelling method (Feinberg & Vogelstein, 1983).
Allele loss of chromosome 17 sequences in tumours was
analysed by Southern analysis using two different VNTR
probes, pYNZ22 (D17S30) and pRMU3 (D17S24), after
digestion with the restriction enzyme TaqI. The localisation
of the different probes used is shown in Figure 1. Tumour
and leucocyte DNA from the same patient was analysed on
the same blot. The samples were scored for allele loss after
the DNA loadings were judged by comparing the same blots
with probes showing non-deleted alleles. If only a weak
reduction of intensity of one allele band was seen, the auto-
radiograms were scanned by the laser scanning method de-






















of some of the markers used for
Immunostainingfor c-erbB-2protein
Frozen sections from the breast carcinomas were immuno-
stained applying a polyclonal antiserum raised in sheep
(Cambridge Research Biochemicals). The c-erbB-2 protein
antibody was raised against a 19 amino acid sequence from
the intracytoplasmic domain of the human c-erbB-2 protein.
The avidin-biotin-peroxidase complex (ABC) method was
used. The sections were treated with hydrogen peroxide to
block endogenous peroxidase, incubated with normal serum
to eliminate non-specific binding before incubation with
specific antiserum (1:100 dilution) followed by sequential
incubations with biotin labelled secondary antibody (1:200
dilution) and then avidin-biotin-peroxidase complex. The
dilution of the primary antibody applied was titred out on
paraffin blocks from a breast carcinoma known to be c-erbB-
2 amplified. The peroxidase reaction was developed using
diaminobenzidin as chromogen. Sections were counterstained
with haematoxylin, dehydrated and mounted. The details of
the procedure have previously been described (Nesland et al.,
1989). Positive and negative controls were performed as well
as absorption controls of the primary antibody. The frozen
sections were incubated with anti c-erbB-2 protein antiserum
preabsorbed with c-erbB-2 protein as well as with EGFR
(Cambridge Research Biochemicals) to exclude potential
cross reactivity with EGFR. All controls gave satisfactory
results.
Oestrogen (ER) andprogesterone receptor (PgR)
determinations
ER and PgR were measured by standard dextran-coated-
charcoal method (DCC) method) in 29 of the primary
tumours and nine of the metastases. In the remaining
tumours ER and PgR were detemined by use of monoclonal
antibodies in an enzyme immunoassay for quantitative
measurement (Abbott ER and PgR-EIA monoclonal).
Statistical analysis
All comparisons between groups and or parameters were
performed using Pearson's x2 analysis with Yates' correction.
In comparisons where the total number was less than 50,
Fisher's exact test was performed. P values <0.05 were
considered statistically significant.
Results
Results of a typical gene amplification and immunostaining
analysis of c-erbB-2 are shown in Figure 2 and 3 respectively.
In our material 20 of the 89 primary breast tumours (22.5%)
had amplification of the c-erbB-2 gene, while 12 of the 24
metastases (50%) had amplification of the gene. This differ-
ence is highly significant (x2 = 7.05, P = 0.016). In one
patient both the primary tumour and two metastases were
examined. The primary tumour was amplified 5-10 times
while the metastases were amplified 15-20 times.
The gene amplification correlated well with the protein
over-expression (x2 = 50.3, P<0.0001) although five samples
with gene amplification failed to show protein excess. The
degree of gene amplification in these samples was moderate,
approximately 2-5 gene copies. In one sample with a high
degree of protein over-expression we did not find gene
amplification. One of the explanations for this protein over-
expression without gene amplification may be that this sam-
ple contains a mutation in the promotor region. Since our
analysis is based on the effect of gene amplification, this
sample was excluded from the further analysis. The immuno-
staining and gene amplification studies were done blindly.
The c-erbB-2 gene amplification in the primary breast
tumours in relation to different clinical parameters is shown
in Table I. A significantly higher proportion of gene ampli-
fication was found in oestrogen receptor negative tumours.
The same difference was observed in the metastases. One out
of nine (11 %) oestrogen receptor positive metastases hadc-erbB-2 AMPLIFICATION AND PROTEIN OVER-EXPRESSION 587
Figure 2 Southern blot analysis showing c-erbB-2 gene
amplification in breast tumours. DNA from three different tissue
samples are shown. The restriction enzyme EcoRI and the neu
cDNA probe were used. The degree of amplification was deter-
mined after rehybridisation of the blot with probe COLIA2,
scanning and adjusting the DNA amount as described. a, tumour
with one gene copy; b, tumour with five gene copies; c, tumour
with 25 gene copies. Figure 3 c-erbB-2 immunostaining of breast carcinomas: a,
tumour with one gene copy and no over-expression ofc-erbB-2; b
and c, tumour with 25 gene copies and over-expression of c-erbB-
2. a and b, x 105; c, magnification x 420.
Table I c-erbB-2 gene amplification in primary tumours in relation to different clinical
variables
Significance Amplified more Significance
Amplified/total level than 5-fold/total level
Significance (%) P (%) P
Tumour size
Ti 7/33 (21%) 5/33 (15%)
T2 4/31 (13%) 2/31 ( 6%)
T3 5/11 (46%) 3/11 (27%)
T4 3/14 (21%) n.s. 3/14 (21%) n.s.
Node status
N=0 7/39(18%) 3/39( 8%)
N > 1 13/50 (26%) n.s. 13/50 (26%) P = 0.062
Clinical stage
I 3/20 (15%) 2/20 (10%)
II 6/39 (15%) 4/39 (10%)
III 8/22 (36%) 6/22 (27%)
IV 2/8 (25%) n.s. 2/8 (25%) n.s.
I +11 9/59 (15%) 6/59 (10%)
III + IV 10/30 (33%) P = 0.09 8/30 (27%) P = 0.087
Premenopausal 8/31 (26%) 5/31 (16%)
Post-menopausal 11/54 (20%) n.s. 9/54 (17%) n.s.
Oestrogen receptor
positive 7/50 (14%) 3/50 ( 6%)
negative 13/42 (31%) P = 0.087 12/42 (29%) P = 0.008
Progesterone receptor
positive 7/48 (15%) 5/48 (10%)
negative 12/41 (29%) n.s. 10/41 (24%) n.s.
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c-erbB-2 amplification, whereas nine out of 15 (60%) oestro-
gen receptor negative metastases were c-erbB-2 amplified
(P = 0.033). An inverse trend was also found between pro-
gesterone receptor content and c-erbB-2 amplification,
although not statistically significant. No significant differ-
ences between amplified and non-amplified tumours were
observed with regard to tumour size, node status, clinical
stage or menopausal status, although borderline significance
was found between high degree of amplification and node
status and clinical stage.
In Table II the distribution of the different histopatho-
logical types between the c-erbB-2 gene amplified and non-
amplified tumours is shown. All the amplified tumours were
of the invasive ductal type.
Analysis of allele losses of chromosome 17p and 17q in 49
of the patients showed that out of 42 patients informative for
17p alleles, 23 (55%) showed allele loss, while of the 29
patients informative for 17q alleles, 14 (48%) showed allele
loss. Eleven of the 27 patients (41%) informative for both
17p and 17q alleles had lost sequences on both arms, indi-
cating loss of the whole chromosome (Table III). Southern
blot analysis showing loss of alleles of 17p are shown in
Figure 4. Loss of alleles on chromosome 17 in relation to
different clinico-histopathological variables is shown in Table
IV. No significant differences were found for any compari-
sons except borderline significant associations between node
positive tumours and loss of 17p, and between patients with
postmenopausal disease and loss of 17q. A trend towards
correlation between high degree of neu amplification and loss
of 17q sequences was found although the data set is small.
However, doing so many comparisons one might expect by
chance that one would lead to a significant result. To support
or reject these findings, analysis in new series therefore have
to be performed.
More than 50% (5/9) of the tumours with c-erbB-2 ampli-
fication also showed loss of 17q sequences. These findings
Table II c-erbB-2 gene amplification in relation to different histo-
pathological types of breast tumours
Amplified/total %
Invasive ductal carc. 29/84 (34%)
Invasive lobular carc. 0/12 (0%)
Othersa 0/5 (0%)
X2 = 8.23, P = 0.016. *Mucinous carcinoma, medullary carcinoma,
lobular carcinoma in situ and intraductal carcinoma.
Table III Allele loss on chromosome 17 in breast tumours
No. ofinformative patients with
Chromosome loss/no. ofinformative patients
Allele loss 17p 23/42 (55%)
17q 14/29 (48%)
Allele loss 17p 4/27 (15%)
restricted to 17q 3/27 (11%)
Allele loss 17p and 17q 11/27 (41%)
for both
indicate that the c-erbB-2 amplification is restricted to one of
the chromosomes.
Family history of breast cancers in relation to c-erbB-2
amplification and loss of 17p and 17q sequences is shown in
Table V. No correlation was found between positive family
history and c-erbB-2 amplification.
Survival data of patients with primary breast tumours and
with an observation time of more than 1 year were available
for 51 patients. Early relapse or death in the c-erbB-2 ampli-
fied group was significantly increased compared to the non-
amplified group (Table VI). However, the numbers are too
small, and the observation time too short to perform any
multivariate analysis of these data.
Table IV Loss of chromosome 17 alleles in relation to clinico-histopathological
parameters
No. ofpatients with loss/no. ofinformative patients (%)
Significance Significance
I7p level 17q level
Tumour size
TI 7/14 (50%) 3/11 (27%)
T2 8/15 (53%) 5/9 (56%)
T3 3/6 (50%) 3/6 (50%)
T4 4/7 (57%) n.s. 3/4 (75%) n.s.
Clinical stage
I 2/5 (40%) 1/5 (20%)
II 13/20 (65%) 7/11 (64%)
III 6/13 (46%) 6/11 (54%)
IV 2/3 (67%) n.s. 0/2 (0%) n.s.
Node status
N = 0 4/12 (33%) 5/10 (50%)
N 1 19/29 (66%) P = 0.087 9/19 (47%) n.s.
Premenopausal 9/15 (60%) 3/11 (27%)
Post-menopausal 14/25 (56%) n.s. 11/17 (65%) P = 0.069
c-erbB-2 gene amplification
positive 6/14 (43%) 5/9 (56%)
negative 17/28 (61%) n.s. 9/21 (43%) n.s.
>5 fold 5/9 (56%) 4/5 (80%)
<5 fold 18/33 (55%) n.s. 10/25 (40%) n.s.
Oestrogen receptor
positive 9/17 (53%) 8/12 (67%)
negative 13/24 (54%) n.s. 6/17 (35%) n.s.
Progesterone receptor
positive 9/18 (50%) 9/13 (69%)
negative 13/22 (59%) n.s. 5/14 (36%) n.s.
Histopathological types
ductal 17/31 (55%) 10/21 (48%)
lobular 3/5 (60%) n.s. 1/4 (25%) n.s.
n.s. = not significant.c-erbB-2 AMPLIFICATION AND PROTEIN OVER-EXPRESSION 589
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Figure 4 Southern blot analysis of normal (N) and tumour
tissue (T) from three different breast cancer patients using the
restriction enzyme TaqI and probe pYNZ22. a and b, loss of
heterozygosity; c, heterozygosity retained.
Table V Family history ofbreast cancer in relation to geneticchanges
in the tumour
c-erbB-2 gene
amplification J7p loss 17q loss
Positive family historya 3/15 (20%) 3/8 (38%) 5/7 (71%)
Negative family history 16/59 (27%) 18/29 (62%) 8/19 (42%)
Significance level n.s. n.s. n.s.
'One or more first degree relative with breast cancer. n.s. = not
significant.
Discussion
Our findings that 22.5% of the primary tumours had ampli-
fication of the c-erbB-2 gene are in agreement with the data
from Slamon et al. (1989). Correction for ploidy by using
other chromosome 17 probes excluded chromosomal duplica-
tion. The higher proportion of c-erbB-2 amplification found
in the metastases, may suggest that patients with an ampli-
fication in their primary tumour are over-represented among
those developing metastases. This would support the hypo-
thesis that amplification correlates with aggressive tumour
behaviour, and thus may play a role as a prognostic factor in
breast carcinomas. However, c-erbB-2 amplification may also
develop during the metastatic process. Studies following the
same patients over time would elucidate this point. In one
patient we were able to study both primary tumour and
several metastases. All of them had gene amplification
although at higher degree in the metastases. This finding
support both hypotheses. The number of patients in our
series is still too small to perform multivariate survival
analyses.
High expression of the c-erbB-2 oncogene has previously
been reported to occur in a significant percentage of intra-
ductal carcinomas (Van der Vijver et al., 1988b). In our study
c-erbB-2 amplification occurred in invasive ductal carcin-
omas. Only two cases of intraductal carcinomas were
included, and none of them expressed c-erbB-2 amplification.
The c-erbB-2 gene encodes a putative growth factor recep-
tor which shows extensive homology with the EGFR and
may be involved in autocrine/paracrine growth regulation.
The negative correlation to the ER and PgR and our
previous finding that c-erbB-2 positive tumours have no pro-
duction of hormones, suggest that there is no or little need
for neuroendocrine differentiation in the c-erbB-2 positive
tumour cells (Nesland et al., 1990). Possibly, c-erbB-2 ampli-
fication may switch off the production of local hormones and
receptors involved in growth modulation. Cells over-express-
ing the c-erbB-2 gene have also been found to have an
increased resistance to tumour necrosis factor (Kartner &
Lig, 1989). Amplification of the gene would thus provide a
mechanism of escaping surveillance of the immune defence
system.
The c-erbB-2 over-expression may offer a growth advant-
age in local disease, and thus contribute to poor prognosis.
Possibly the gene must act in concert with other tumouri-
genic events in order to express its full potential in systemic
disease. The inactivation of tumour suppressor genes may be
one such event. Loss of heterozygosity for markers on
chromosome 17p has pointed to a putative suppressor gene
on this chromosome involved in both lung, colon and breast
cancer. Our observation of a 55% loss of 17p is in agreement
with others (MacKay et al., 1988; Devilee et al., 1989).
However, in contrast to MacKay et al. (1988) we found a
higher frequency of loss of 17q as well, indicating that a
number of tumours had lost the whole chromosome 17.
In the first part of this study (30 patients) we found a
significant negative correlation between loss of 17q sequences
and gene amplification of the c-erbB-2 gene residing on 17q
(B0rresen et al., 1990). The same trend, although not statis-
tically significant, was seen when a high degree of ampli-
fication, and loss of 17q were compared in the total series.
The biological meaning of these findings is unclear and
studies to elucidate if the loss of sequences of chromosome
17 is enhanced by the amplification or vice versa are under
way.
Heritable lesions affecting several tumour suppressor genes
seem to determine genetic susceptibility to malignancies
behaving as autosomal dominant disorders with variable
penetrance. This pattern of inheritance is believed to under-
lay at least a part of the familial aggregation of breast
cancers. Chromosome 17p has been suggested as a candidate
region for linkage analyses in breast cancer families. How-
ever, in our studies no correlation to positive family history
of breast cancers were seen. On the contrary, a trend towards
a negative correlation between family history and loss of 17p
was seen, although this was not statistically significant. Other
putative tumour suppressor genes involved in breast tumours
have been reported on chromosome 11 and chromosome 13.
We found loss of sequences ofchromosome 11 in 12% of the
tumours, and loss of sequences within the retinoblastoma
gene on chromosome 13 in 35% of the tumours (Gaustad et
al., 1990). The positive correlation found between loss of





Status ofpatients >S-fold <S-fold level
All patients alive, well 3 31
recurrency or dead 8 9 x2 =9.74
P= 0.006
Patients with node alive, well 2 23
status = 0 recurrency or dead 0 1 n.s.
Patients with node alive, well 1 8
status > 0 recurrency or dead 8 8 x2 = 3.78
P = 0.05
n.s. = not significant.590 A.-L. B0RRESEN et al.
retinoblastoma sequences and loss of 17p sequences (Gaustad
et al., 1990), indicate that several oncogenes and suppressor
genes may be involved in the carcinogenesis of breast
tumours. The inactivation of tumour suppressor genes and
the activation of one or more oncogenes appear to be subse-
quent steps on the route towards malignancy in the breast.
The sequence of these genetic events and the genetic charac-
teristics of different tumour subtypes with characteristic bio-
logical features, is still unknown. Studies of different genetic
alterations in larger series of tumours with known clinical
outcome is needed. Studies of genetic alterations at different
stages of the diseases may also reveal which alterations lead
to a more malignant phenotype, and which alterations just
reflect genetic instability. The different changes in oncogenes
and tumour suppressor genes will hopefully be of use in the
diagnosis and management of breast cancer.
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